Soleno Therapeutics Debt 2024

Soleno Therapeutics Debt

-169.68 USD

Soleno Therapeutics Dividend yield

Ticker

SLNO

ISIN

US8342032005

WKN

A2JSTG

In 2024, Soleno Therapeutics's total debt was -169.68 USD, a 1,062.2% change from the -14.6 USD total debt recorded in the previous year.

Soleno Therapeutics Aktienanalyse

What does Soleno Therapeutics do?

Soleno Therapeutics Inc is a biopharmaceutical company focused on rare diseases and unmet medical needs. The company was founded in 1999 and is headquartered in Redwood City, California. Soleno Therapeutics develops and markets innovative therapies for patients who have previously had limited or no treatment options. Business model: Soleno Therapeutics specializes in developing therapies for rare diseases. The company takes an innovative approach and utilizes cutting-edge technologies to develop drugs that have the potential to improve the lives of affected patients. The company works closely with leading research institutions and experts in the industry and invests significantly in research and development of new therapies. The company employs a two-pronged approach, developing innovative drugs for unmet medical needs while also acquiring already approved drugs and optimizing them for new applications. Soleno Therapeutics then markets these drugs to physicians, hospitals, and patients worldwide. Segments: Soleno Therapeutics specializes in developing therapies for rare diseases, focusing on three main segments: 1. Hypophosphatasia: Hypophosphatasia is a rare metabolic disorder that leads to the accumulation of phosphate in the bones and tissues. This results in weak bones, pain, and a variety of other symptoms. Soleno Therapeutics has developed a novel enzyme replacement therapy product that aims to support bone formation and alleviate the symptoms of the disease. 2. Prader-Willi Syndrome: Prader-Willi Syndrome is a rare genetic disorder characterized by obesity, mental retardation, and hormonal imbalances. Soleno Therapeutics has developed a product that suppresses hunger, helping patients develop a normal diet and achieve a healthy weight. 3. Other indications: Soleno Therapeutics is also working on developing therapies for other rare diseases and unmet medical needs, including conditions such as hemophilia, narcolepsy, and Parkinson's. Products: Soleno Therapeutics currently offers the following products: 1. Treakisym: Treakisym is a novel enzyme replacement therapy product aimed at supporting bone formation in patients with hypophosphatasia. The medication has already been approved in Japan. 2. Solinum: Solinum is a product that suppresses hunger in patients with Prader-Willi Syndrome. The medication is currently in Phase III of clinical trials and is expected to be approved in the coming years. 3. Other products: Soleno Therapeutics also has a range of other products in the pipeline, focusing on the development of therapies for rare diseases. Conclusion: Soleno Therapeutics is an innovative biopharmaceutical company specializing in the development of therapies for rare diseases and unmet medical needs. The company invests significantly in research and development of new medications and works closely with industry experts. Soleno Therapeutics has already launched an enzyme replacement therapy product for hypophosphatasia and is currently working on the approval of a hunger suppressant product for Prader-Willi Syndrome. The company also has a range of other medications in the pipeline, aiming to improve the lives of patients with rare diseases. Soleno Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Soleno Therapeutics's Debt Structure

Soleno Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Soleno Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Soleno Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Soleno Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Soleno Therapeutics Stock

What is the debt of Soleno Therapeutics this year?

Soleno Therapeutics has a debt level of -169.68 USD this year.

What was the debt of Soleno Therapeutics compared to the previous year?

The debt of Soleno Therapeutics has increased by 1,062.2% compared to the previous year increased.

What are the consequences of high debt for investors in Soleno Therapeutics?

High debt can pose a risk for investors of Soleno Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Soleno Therapeutics?

Low debt means that Soleno Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Soleno Therapeutics affect the company?

An increase in debt of Soleno Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Soleno Therapeutics affect the company?

A reduction in debt of Soleno Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Soleno Therapeutics?

Some factors that can influence the debt of Soleno Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Soleno Therapeutics so important for investors?

The debts of Soleno Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Soleno Therapeutics take to change the debt?

To change the debt, Soleno Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Soleno Therapeutics pay?

Over the past 12 months, Soleno Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Soleno Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Soleno Therapeutics?

The current dividend yield of Soleno Therapeutics is .

When does Soleno Therapeutics pay dividends?

Soleno Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Soleno Therapeutics?

Soleno Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Soleno Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Soleno Therapeutics located?

Soleno Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Soleno Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Soleno Therapeutics from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Soleno Therapeutics pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Soleno Therapeutics in the year 2023?

In the year 2023, Soleno Therapeutics distributed 0 USD as dividends.

In which currency does Soleno Therapeutics pay out the dividend?

The dividends of Soleno Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Soleno Therapeutics

Our stock analysis for Soleno Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soleno Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.